Regarding: Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Regarding: Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%

Published:2022-01-18 Issue:5 Volume:291 Page:705-706
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

Almagro Pere¹²^ORCID,Malik Komal¹,Martínez‐Camblor Pablo³⁴

Affiliation:

1. Internal Medicine Service Hospital Universitario Mutua de Terrassa Terrassa Spain

2. Medicine University University of Barcelona Barcelona Spain

3. Department of Anesthesiology Dartmouth‐Hitchcock Medical Center Lebanon New Hampshire USA

4. Biomedical Data Sciences Department Geisel School of Medicine at Dartmouth Hanover New Hampshire USA

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/joim.13438

Reference7 articles.

1. Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%: A population‐based nested case–control study

2. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline

3. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials

4. Increased Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease and the Potential Mechanisms Linking the Two Conditions

5. Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacotherapy of LAMA/LABA inhaled therapy combinations for chronic obstructive pulmonary disease: a clinical overview;Expert Review of Clinical Pharmacology;2022-11-02

2. Authors reply: Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%;Journal of Internal Medicine;2022-01-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3